These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9851517)

  • 1. Cellular vaccines.
    Bartholeyns J; Romet-Lemonne JL; Chokri M; Buyse M; Velu T; Bruyns C; Van de Winkel JJ; Heeney J; Koopman G; Malmsten M; De Groote D; Monsigny M; Midoux P; Alarcon B
    Res Immunol; 1998; 149(7-8):647-9. PubMed ID: 9851517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC; Abrams JT; Zhang SY; Galili U
    Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell-directed cancer vaccines: the melanoma model.
    Wang E; Phan GQ; Marincola FM
    Expert Opin Biol Ther; 2001 Mar; 1(2):277-90. PubMed ID: 11727535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines.
    Colluru VT; McNeel DG
    Oncotarget; 2016 Oct; 7(42):67901-67918. PubMed ID: 27661128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cells and T cells in immunotherapy.
    O'Neill DW
    J Drugs Dermatol; 2010 Nov; 9(11):1383-92. PubMed ID: 21061761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
    Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
    Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
    Sims RB
    Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer vaccines.
    Greten TF; Jaffee EM
    J Clin Oncol; 1999 Mar; 17(3):1047-60. PubMed ID: 10071300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice.
    Haabeth OAW; Blake TR; McKinlay CJ; Waymouth RM; Wender PA; Levy R
    Proc Natl Acad Sci U S A; 2018 Sep; 115(39):E9153-E9161. PubMed ID: 30201728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of antigen-presenting cells in long-term antitumor response based on tumor-derived apoptotic body vaccination.
    Henry F; Bretaudeau L; Hequet A; Barbieux I; Lieubeau B; Meflah K; Grégoire M
    Pathobiology; 1999; 67(5-6):306-10. PubMed ID: 10725809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
    Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically modified tumour vaccines--where we are today.
    Nawrocki S; Mackiewicz A
    Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor vaccination: where we stand.
    Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo.
    Singh NP; Miller RW; Yolcu ES; Kilinc MO; Oechsli M; Huseby R; Taylor DD; Perry MT; Larocca RV; Shirwan H
    Hum Gene Ther; 2006 Mar; 17(3):334-46. PubMed ID: 16544982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines.
    Jarnjak-Jankovic S; Hammerstad H; Saebøe-Larssen S; Kvalheim G; Gaudernack G
    BMC Cancer; 2007 Jul; 7():119. PubMed ID: 17608923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells.
    Leen A; Ratnayake M; Foster A; Heym K; Ahmed N; Rooney CM; Gottschalk S
    J Immunother; 2007 Jan; 30(1):96-107. PubMed ID: 17198088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral vectors for gene transfer into antigen presenting cells.
    Monahan SJ; Salgaller ML
    Curr Opin Mol Ther; 1999 Oct; 1(5):558-64. PubMed ID: 11249662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.
    Yang S; Tsang KY; Schlom J
    Clin Cancer Res; 2005 Aug; 11(15):5603-15. PubMed ID: 16061879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.